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Abstract  
This article explores the use of multivariate techniques to build perceptual maps that 
show the perceived competitive positions of a set of ethical drugs. The data were drawn 
from a commercial panel of 283 family doctors working for the UK National Health 
Service. Factor analysis was applied to identify the main dimensions used by doctors to 
perceive and evaluate antihypertensive brands. Perceptual maps showing the 
competitive positions of 14 antihypertensives were produced using the factor scores of 
the medicines. Multiple regression analysis enabled the relative importance of each 
perceptual dimension to be determined. The results reveal that doctors use a small 
number of perceptual dimensions to evaluate competitive antihypertensive drugs, 
namely: “medical support”, “long term efficacy”, and the “additional beneficial effects” 
provided by the brand. The implications for marketing managers in the ethical 
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 2 
pharmaceutical industry are explained and ways in which the perceptual analysis can be 
used to guide strategic marketing decisions considered. 
 
 
Keywords: Marketing; Ethical pharmaceutical products; Prescribing behaviour; 
Multivariate statistical analysis; Perceptual mapping 
 
 
1. Introduction 
Understanding how buyers perceive competitive offerings is paramount in the 
development of competitive marketing strategies, not only for consumer and industrial 
offerings (e.g, Kotler and Keller, 2006; Dibb et al. 2005, Hooley et al., 2004) but also 
for ethical pharmaceutical products or prescription drugs (Vanderveer and Pines, 2007; 
Lidstone and MacLennan, 1999; Smarta, 1996; Corstjens, 1991). Perceptual mapping, 
an important analytical tool in marketing research, is commonly used to investigate the 
perceptions of buyers (Green et al., 2003, 1988; Neal, 1988; Hauser and Koppelman, 
1979) and can also support the development of marketing strategies. However, the 
multivariate statistical techniques for building perceptual maps used in consumer and 
industrial markets have not yet spread through the ethical pharmaceutical industry. This 
research aims to extend literature on perceptual mapping by using factor analysis to 
produce perceptual maps that reveal the perceived competitive positions of prescription 
drugs. 
 
The paper is organised as follows. Firstly, a literature review on perceptual mapping and 
its support for strategic marketing decisions is presented. Secondly, details of the data 
and the empirical study are shown. Thirdly, factor analysis is used to determine the 
main perceptual dimensions doctors use to evaluate the competitive antihypertensive 
drugs analysed. Fourthly, the perceptual maps are built.  These use the ethical drugs’ 
factor scores and the results of cluster analysis to display the perceived competitive 
positions of ethical pharmaceutical products and product classes in the sample. Fifthly, 
the relative importance of the main evaluative dimensions is determined with multiple 
regression analysis. Ways in which the applied methodology can be used to improve the 
competitive position of ethical brands are then considered. Finally, the study’s 
conclusions are presented and further research directions proposed.   
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2. Supporting Strategic Marketing Decisions with Perceptual Maps 
According to Shocker (1987), the aim of perceptual mapping is to model how a market 
sees a set of competing products “in some memory-like or cognitive sense”. Perceptual 
mapping techniques are able to represent the competitive structure of markets “in a 
(visual) manner that facilitates differentiation and positioning decisions” (Lilien and 
Rangaswamy, 2003). As people process pictures faster than text (Paivio et al., 1968), it 
is easier to see and interpret relationships when they are presented graphically than in 
tables with numbers (Cahill, 1995). Perceptual mapping methods capture customers’ 
perceptions of competitive offers, which are then displayed in perceptual maps with few 
strategic dimensions. Each axis represents a key dimension used by customers to 
perceive and judge competitive offers. Perceptual mapping is frequently used to 
position or reposition an offer, to measure the success of positioning or repositioning 
exercises, or to monitor the evolution of the positioning of competitive brands over time 
(Neal, 1980). It can uncover unfulfilled gaps in the market, the perceived relative 
strengths and weaknesses of competitive products, the intensity of rivalry between 
specific competitive offers, and opportunities for gaining a differentiated position. 
Moreover, “its powerful graphic simplicity appeals to senior management and can 
stimulate discussion and strategic thinking at all levels of all types of organizations” 
(Wittenschlaeger and Fiedler, 1997). Together these qualities have made perceptual 
mapping a valuable strategic management tool. 
 
Analytical methods for developing perceptual maps can be categorised into 
compositional and decompositional approaches (Green et al., 1988). Compositional 
methods assume that consumers can decompose their perceptions of brands into 
separate attributes and can evaluate each brand according to these attributes. Brand 
perceptions based on these attributes are first gathered with direct measures; a 
multivariate technique is then used to reduce the original number of product attributes to 
a small number of strategic dimensions, and the competitive offerings are plotted using 
their scores along these new dimensions. Multivariate techniques generally used with 
compositional approaches are factor analysis, discriminant analysis and, when the input 
is nominal data, correspondence analysis (Johnson, 1999; Neal, 1988).  
 
ACCEPTED MANUSCRIPT 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 4 
Decompositional methods assume that people have global perceptions of objects which 
cannot be decomposed. This requires a perceptual map based on overall comparisons 
between competitive offerings, so that the researcher does not specify an attribute set. 
The aim is to identify the relative positions of the products based on customers’ 
judgements of the similarity/dissimilarity of competitive offers. Decompositional 
approaches use a variety of nonmetric multidimensional scaling methods, for example 
KYST (Kruskal, 1964a and 1964b). Compositional methods have been found to be 
superior to decompositional methods in terms of theory, interpretability of the 
dimensions, ease of use, and predictive validity (Hauser and Koppelman, 1979).  
However, Shocker (1987) argues that these two classes of methods should be viewed as 
complements rather than as substitutes. This is because compositional methods place “a 
great burden on the researcher to correctly develop a set of attributes and ways of 
scaling products on those attributes before the analysis begins”, whereas 
decompositional methods “by allowing the consumer to impose his/her own structure … 
may even suggest attributes of products that might otherwise not have come to mind”.  
 
Perceptual maps can capture the preferences (the most valued region of the perceptual 
space) as well as the perceptions of respondents, thus showing which products/brands 
are most attractive. The ideal point model assumes that respondents prefer a point in the 
perceptual space corresponding to their ideal product/brand. Isopreference curves, 
where products/brands lying on the same curve have equal preferences, are developed 
taking the ideal point as the centre. The most preferred products/brands are those 
positioned on the isopreference curves closest to centre (Van Deun et al., 2005). By 
contrast, the vector model, which assumes that respondents have a preferred direction in 
the perceptual space, calls for the identification of an ideal vector along which a 
product/brand should be moved to maximise customer preference; products/brands 
equally preferred are those positioned on the same perpendicular to the ideal vector 
(Urban and Hauser, 1993; Shocker, 1987).   
 
According to Myers (1992), perceptual mapping has its origins in the work of Hotelling 
(1929), an economist who began developing techniques for positioning objects in 
virtual spaces long before psychologists in the 1950s. The use of perceptual mapping 
techniques has been widespread in quantitative marketing research since the 1960s, with 
the importance of perceptual mapping methodologies in marketing research likely to 
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continue (Green et al., 2003). Numerous studies have produced perceptual maps for 
objects as diverse as countries, new product concepts, beer brands, cities, automobiles, 
psychology journals, movie critics, cereal brands, human genes, areas of economic 
activity, food products and diet concepts, breath freshener products, and financial 
services (see for example, Lattin et al. (2003) and Shocker (1987)). Even perceptual 
maps for brands of king size cigarettes have been developed (Hooley, 1984). 
 
Recent studies have considered the production of perceptual maps for the brand image 
of deodorants (Torres and Bijmolt, 2009), travel agencies (Kim D. et al., 2007), political 
candidates (Kamakura and Mazzon, 2007), restaurants (Natasa et al., 2007), top journals 
from various academic business disciplines (Biehl et al., 2006), leather products (Faye 
et al., 2006), print advertisements of automobiles (Hartmann et al., 2005), tourism 
destinations (Kim S. et al., 2005), development of cities (Festervand, 2004), casinos 
(Kim W. et al. 2004), image of destinations (Kozak et al., 2003), and states of USA 
(Chen and Uysal, 2002). Multidimensional scaling methodologies are the most widely 
used, followed by correspondence analysis and factor analysis.  
 
However, there are very few published studies using quantitative perceptual maps to 
support competitive marketing strategies in the ethical pharmaceutical industry. Only 
three studies using multivariate perceptual mapping techniques have been published in 
this area. The study by Neidell (1969) used nonmetric multidimensional scaling 
techniques to produce perceptual maps for six competing ethical drugs, including one 
ideal brand, from two therapeutic classes of medicines, namely the ataractics 
(tranquilizers) and anorectics (anti-obesity drugs). The second study used 
correspondence analysis to develop perceptual maps showing the perceived positions of 
six competitive medicines belonging to the ethical analgesics market; these maps were 
used to guide the repositioning of an ethical drug (Hurrell et al., 1997). The third study, 
which actually analyses preference rather than perceptual data, used a spatial gravity 
multidimensional scaling methodology to derive a two dimensional joint space showing 
seven prescription brands, from an unrevealed market, and the physicians’ ideal points 
(DeSarbo et al., 2002).  
 
Surprisingly, although factor analysis has been widely used to identify consumer choice 
dimensions and to display the perceptual positions of competitive offers (Neal, 1988; 
ACCEPTED MANUSCRIPT 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 6 
Shocker, 1987), it has never been applied in the ethical pharmaceutical industry or in 
related areas such as over-the-counter, dental or veterinary medicine. This research is 
the first to apply factor analysis
1
, a compositional approach, to produce perceptual maps 
that reveal the perceived competitive positions and the key drug choice dimensions of a 
set of ethical pharmaceutical brands. This study uses fourteen ethical drugs, which is a 
much larger number in comparison with those used in previous studies. For some very 
competitive ethical markets pharmaceutical managers might benefit from having 
perceptual competitive information on a large set of drugs. In addition, this is the first 
time that multivariate perceptual mapping techniques have been used to research the 
antihypertensives market. The vector model is used to capture the relative importance of 
the choice dimensions, therefore assuming that doctors use dimensions where “more (or 
less) is better”. This methodology should improve the knowledge of how doctors choose 
the drugs they prescribe and support marketing managers in developing better strategies 
and practices to match the needs of target doctors.  
 
3. Data and Empirical Study   
This research examines the antihypertensive drugs market. Antihypertensive medicines 
are used to control high blood pressure (hypertension), a disease affecting around one 
billion people worldwide (Kearney et al., 2005; JNC 7 report, 2004). Various categories 
of drugs are used to treat hypertension, each lowering blood pressure through a different 
mechanism
2
. Although the treatment of hypertension varies from country to country 
(Fretheim and Oxman, 2005), any drug from each category can be used as first line 
therapy in the treatment of mild hypertension (Psaty et al., 2003).  
 
This study uses panel data from an international market research company serving the 
pharmaceutical industry. The doctors’ panel consists of a stratified sample of 283 family 
                                                 
1
 Factor analysis permits the researcher to work with a larger set of competitive offerings when compared 
to nonmetric multidimensional scaling techniques; the perceptual maps resulting from factor analysis are 
easier to interpret by decision makers compared with those arising from correspondence analysis. 
2
 Diuretics reduce the volume of blood by increasing the flow of urine excretion; Betablockers slow down 
the heart beat; Calcium Antagonists relax the blood vessels by blocking the flow of the calcium ions into 
the muscles; ACE inhibitors block angiotensin converting enzyme (ACE) to prevent the formation of 
angiotensin II, which is a potent constrictor of blood vessels; and Alphablockers block alpha-1 adrenergic 
receptors in blood vessels, causing vasodilatation.  
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 7 
doctors working for the UK National Health Service (NHS), balanced to represent the 
UK population of family doctors (general practitioners). Family doctors were selected 
on the basis of their regional distribution across the UK. 
 
Family doctors working for the NHS prescribe around 80 % of all antihypertensive 
drugs sold in UK. Participating doctors regularly complete a quarterly twenty-page 
questionnaire; data in this research refers to the first quarter. This secondary data were 
highly appropriate for the research, since it used a suitable sample and asked suitable 
questions about attitude, reported prescribing frequency and demographic details of 
doctors and their practices. The information relates to the main prescription drugs from 
the different antihypertensive classes and includes information on all relevant needs 
concerning their prescription. All of the 283 doctors returned filled questionnaires. 
Cases where more than 15 % of the data were missing were specifically excluded. The 
remaining 232 questionnaires were used in the analysis. Missing data for the attitude 
and reported prescribing frequency were replaced by the corresponding average value 
across all doctors, whereas demographic details were left as missing. 
 
Both the sampled drugs and the questions in the questionnaire were selected by 
pharmaceutical marketing experts specialising in hypertension from the major 
international drug companies. These companies pay a fee to have their ethical drugs and 
questions included in the questionnaire. Fourteen main antihypertensive drugs from the 
major antihypertensive therapeutic drug classes were used, namely two Diuretics (coded 
as D1 and D2), three Betablockers (coded as BB1, BB2 and BB3), three Calcium 
Antagonists (coded as CA1, CA2 and CA3), four ACE-inhibitors (coded as ACE1 to 
ACE4), and two Alphablockers (coded as AB1 and AB2).  
 
A literature review on antihypertensive prescribing was conducted and exploratory 
interviews with family doctors were carried specifically for this research. These ensured 
the questionnaire included all important doctors’ needs concerning the prescription of 
antihypertensive drugs. The literature review revealed that all the main antihypertensive 
prescribing need concepts/variables presented in other studies are measured with the 
ACCEPTED MANUSCRIPT 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 8 
variables used in this questionnaire
3
. The variables which were most used in the studies 
are those related to efficacy, side effects, cost, patient compliance, and approval by 
colleagues. Efficacy and side effects of the drug were used in all reviewed studies; cost 
of the drug, either the cost of the drug for the health care system or the cost for the 
patient, was used in 10 of these studies; patient compliance, either as patient compliance 
or as dosage schedule, was used in 8 of the reviewed studies; approval by colleagues, 
was used under the names of approval by colleagues, colleagues’ approval, colleague 
opinion, or acceptance by peers, in 6 studies, namely in those by Denig et al. (1993), 
Denig et al. (1988), Chinburapa and Larson (1988), Segal and Hepler (1985), Segal and 
Hepler (1982), and Harrel and Bennett (1974).  
 
A series of pilot unstructured interviews of approximately one hour with a convenience 
sample of 6 family doctors confirmed that the three variables not identified in the 
literature correspond to additional antihypertensive prescribing needs, namely those 
concerned with the quality of life of the patient (variable “Improves patient’s quality of 
life”) and with the medicine’s additional beneficial effects (variables “Cardio-Protective 
Drug” and “Benefits the Whole Cardiovascular System”).  
 
Doctors’ prescribing attitudes were measured on a seven-point Likert scale (1 = 
“Strongly agree” to 7 = “Strongly disagree”). The attitude variables names and codes 
are presented in Table 1. Family doctors were also asked to indicate how frequently 
they used each drug in the treatment of hypertension, again using a seven-point Likert 
scale. This type of Likert scales are commonly used in marketing research (e.g. Bruner 
et al., 2005). 
 
[Insert Table 1] 
 
The data analysis (using SPSS for Windows) used factor analysis to determine the main 
perceptual dimensions used to evaluate competitive antihypertensive drugs, cluster 
analysis to identify the different perceived categories of ethical drugs, and multiple 
                                                 
3
 Greving et al., 2006; Denig et al., 1993; Chinburapa and Larson, 1993; Jernigan, 1991; Chinburapa and 
Larson, 1988; Denig et al., 1988; Chinburapa et al., 1987; Segal and Hepler, 1985; Epstein et al., 1984; 
Segal and Hepler, 1982; Lilja, 1976; Harrel and Bennett, 1974. 
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 9 
regression analysis to find the relative importance of the main perceptual dimensions. 
All multivariate techniques were first run on an analysis sample comprising two thirds 
of the doctors. They were then run on a validation sample comprising the remaining one 
third of doctors.  The analysis and the validation sample were randomly generated.  
Tables 2–6 and Figures 1–6 refer to the results obtained from the analysis sample. 
  
4. Determining the Main Perceptual Prescription Drug Choice Dimensions  
The perceptual dimensions used by family doctors to evaluate antihypertensive drugs 
can be identified using factor analysis, a multivariate technique for exploring the 
interdependence among observed variables (Kim and Mueller, 1978). Exploratory factor 
analysis was used to reduce, with minimum loss, the information contained in the 
observed variables into a smaller group of factors, or dimensions (Gorsuch, 1983). 
Since it can cope with any data distribution, principal components method with varimax 
rotation was used to identify the few perceptual dimensions that account for most of the 
variance in the measured perceptual data. According to DeSarbo et al. (2007), “this is 
one of the foremost multivariate methods utilized in marketing and business research 
for data reduction”. Principal components method has, for example, recently been used 
to identify the main axes of socio-economic development of European regions (Del 
Campo et al., 2008); investigate how decision makers characterize alternatives in 
important decisions (Svenson and Halo, 2007); examine basic financial characteristics 
of banks (Canbas et al., 2005); search for patterns of supply chain practices (Yusuf et 
al., 2004); and identify the socio-economic development dimensions of a country’s 
territory (Soares et al., 2003).   
 
Principal components analysis was carried out on the analysis sample (two thirds of 
doctors), with the factor structure then validated on the validation sample (the remaining 
one third). A table of all doctors and all drugs (vertical axis), and all attribute variables 
(horizontal axis) was built for each sample, and each table was subjected to the 
following procedure: (i) the correlation matrix of all variables was used to evaluate the 
appropriateness of the factor model; (ii) the number of factors to be extracted and the 
assessment of the model fit with the original data was determined; (iii) varimax rotation, 
which imposes an orthogonal structure on the data, was applied to make the factors 
more interpretable; (iv) factor scores for each case were computed for use in subsequent 
statistical analysis. 
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The suitability of the data for factor analysis was checked by looking at the correlation 
matrix for all variables and by computing the Bartlett’s (1950) test of sphericity and the 
Kaiser–Meyer–Olkin (KMO) measure of sampling adequacy (Hair et al., 2006). The 
correlation matrix for the 21 attributes is shown in Table 2; all but 11 correlations in this 
matrix are significant at the 0.01 level. Seventeen variables have at least one correlation 
coefficient greater than 0.4, with the remaining four variables having at least one 
correlation coefficient exceeding 0.3. This is consistent with Kinnear and Gray (1999) 
who indicate that variables with coefficients greater than 0.3 can be included in the 
analysis. Therefore, all 21 variables satisfied the conditions for inclusion in the analysis. 
Bartlett’s (1950) test of sphericity was used to test the hypothesis that the correlation 
matrix is an identity matrix. With a value of 15706.2, the probability associated with 
this test is smaller than 0.001. The hypothesis was rejected, meaning that it is unlikely 
that the correlation matrix is an identity matrix and that the matrix is appropriate for 
factor analysis. Finally, the KMO value of sampling adequacy was found to be 0.88, a 
figure that Kaiser and Rice (1974) classify as meritorious, suggesting the data are 
suitable for factor analysis. 
 
[Insert Table 2] 
 
The criteria considered to determine the number of factors to extract were the (i) 
eigenvalue criterion; (ii) the scree test criterion (Catell, 1966); (iii) the percentage of 
variance criterion; and (iv) the interpretability of the factor structure solution (Hair et 
al., 2006; Kline, 1994). The eigenvalue criterion suggests retaining all factors with 
eigenvalues greater than 1. Five of the eleven factors extracted in the principal 
components analysis satisfied this criterion (see Table 3).   
 
[Insert Table 3] 
 
The scree test indicates that the maximum number of factors to extract is given by “the 
point at which the curve first begins to straighten out” (Hair et al., 2006). In general, the 
scree test suggests the extraction of up to three more factors than the eigenvalue 
criterion. Since a straight line would fit the eigenvalues of factors 6–21, the scree plot in 
Figure 1 indicates that a maximum of six factors should be extracted. However, it could 
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be argued that the “elbow” in the eigenvalues might suggest that three factors should be 
extracted; for this reason the three factor solution was also evaluated. This kind of 
interpretation is appropriate since researchers recognised that the scree test criterion is 
not an exact measure, and “involves judgment of where the discontinuity in eigenvalues 
occurs” (Tabachnick and Fidell, 2007). 
 
[Insert Figure 1] 
 
The percentage of variance criterion recommends extracting the factors accounting for 
at least 60 % of the original variance, a cut-off point which is normally accepted as 
satisfactory for social science research. According to this criterion at least five factors 
should be extracted (see Table 3). 
 
Finally, the factor solutions identified as a consequence of the first three criteria were 
subjected to the interpretability test. The ability to interpret and assign meaning to the 
factors is an important consideration in determining how many factors to extract (Hair 
et al., 2006). Principal components analysis with varimax rotation was used to derive 
four alternative factor structures retaining three, four, five and six factors. The most 
readily interpretable solution was obtained when five factors were retained (see Table 
4).   
 
[Insert Table 4] 
 
Considering the assessment of the selected factorial structure, Hair et al. (2006) suggest 
that factor loadings greater than 0.30 are considered minimally acceptable, whereas 
loadings greater than 0.50 are considered significant. Following the procedure used by 
Lattin et al. (2003), to make it easier to read the factor structure factor loadings greater 
than 0.40 are displayed in bold in Table 4. Assessing this model reveals a number of 
positive features.  Firstly, all variables have significant loadings, except three variables 
which have acceptable factor loadings of between 0.40 and 0.50. Secondly, seventeen 
variables load highly on only one factor, whereas only four variables load highly on two 
factors. Thirdly, the five factor solution accounts for between 49 % and 73 % of the 
variance for each individual variable. Finally, the first five factors account for more than 
60 % of the total variance of the original variables.  
ACCEPTED MANUSCRIPT 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 12 
 
Since four of the variables load highly on more than one factor, the question of 
discriminant validity is raised.   However, as three of these variables (UDC, ACP, and 
EFS) clearly have higher loadings on one factor, and given the overall intuitive logic of 
the factor structure, this is not considered to be a major concern (Hair et al., 2006).   
 
Turning to the labelling of factors, the first factor, which accounts for around 19 % of 
the total variance, is called the “additional beneficial effects” of the drug, since the 
variables with higher loadings on this factor are “benefits the whole cardiovascular 
system”, “regresses left ventricular hypertrophy”, and “has a beneficial effect on serum 
lipid profile” (factor loadings between 0.65 and 0.73). Lower scores on this factor mean 
higher “additional beneficial effects”. 
 
The second factor, which accounts for 13 % of total variance, is named “long term 
efficacy” of the drug. Two variables with high loadings are “offers long term control of 
hypertension” and “effectively lowers systolic blood pressure” (0.73 and 0.60 
respectively). It seems that long term treatment of hypertension is easily achieved with 
drugs which have simpler dosage regime, since the variable “a very simple dosage 
regime” also loads highly only on this factor, with a value of 0.63. Lower scores on this 
factor reflect higher “long term efficacy”. 
 
Factor three accounts for around 12 % of total variance and is named perceived 
“medical support”, because it reflects the medical support the drug receives from 
professionals. High loadings on this factor are for variables “first line treatment in 
hypertension”, and “widely recommended by local consultants” (0.80 and 0.57 
respectively). Drugs with high “medical support” are also highly useful for mild 
hypertension, since the variable “a useful drug for use in mild cases of hypertension” 
also loads highly on this factor (loading of 0.76). Lower scores on this factor reflect 
higher perceived “medical support”. 
 
The fourth factor, which accounts for about 9 % of total variance, clearly reflects the 
“adverse side effects” of the drug. The only three variables that load high on this factor 
are all related to adverse side effects of antihypertensive drugs. The two variables that 
load highly on this factor are “tends to cause postural hypotension” and “occasionally 
ACCEPTED MANUSCRIPT 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 13 
will produce severe side effects” (0.73 and 0.72 respectively). Lower scores on this 
factor reflect higher “adverse side effects”. 
 
Only the variable “very suitable for asthmatic and bronchitic patients” loads highly on 
factor five (0.81). This factor, which accounts for around 8 % of total variance, thus 
reflects the “asthmatic and bronchitic suitability” of the drug for patients with these 
additional conditions, is named accordingly. Lower scores on this factor mean the drug 
is more suitable for asthmatic and bronchitic patients. 
 
Factor scores were computed for each case, so that each was represented by a smaller 
set of scores based on the derived perceptual dimensions. These scores, which were 
obtained using the regression method, have a mean of zero and a standard deviation of 
one. 
 
A five factor solution was also found when the validation sample was subjected to the 
same analysis with an almost identical factor structure being produced. There were 
similar factor loadings, the percentage of variance explained was similar (16.3 %, 14.8 
%, 13.4 %, 7.5 %, and 7.4 % for rotated factors F1, F2, F3, F4, and F5 respectively), as 
was the cumulative percentage of variance explained (59.5 %), and communalities (with 
values between 0.48 and 0.72). 
 
5. Building Perceptual Maps Showing the Perceived Competitive Positions of 
Prescription Drugs 
The competitive positions of the 14 antihypertensive drugs were established by deriving 
perceptual maps displaying each brand’s average factor score, across all doctors, on 
each perceptual dimension (see Figures 2–4). Figure 2 shows the perceptual map 
revealing the competitive positions of the ethical drugs analysed in relation to 
dimensions F1 - “additional beneficial effects” and F2 - “long term efficacy”; Figure 3 
provides similar information based on dimensions F1 and F3 - “medical support”, 
whereas the perceptual map show in Figure 4 is based on dimensions F4 - “adverse side 
effects” and F5 - “asthmatic and bronchitic suitability”. These perceptual maps offer a 
useful way of viewing the perceived relative positions of the various ethical drugs along 
the five derived dimensions. They also show the main perceived differences between 
individual and categories of ethical drugs. 
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Figure 2 reveals that ACE2 is perceived as delivering the best “additional beneficial 
effects” of all ethical drugs in the sample, whereas the diuretic D1 is at the other 
extreme of this perceptual dimension. Figure 2 reveals that ACE3, ACE4, ACE1 and 
CA2 constitute the group of prescription medicines best perceived conjointly in terms of 
dimensions F1 and F2. Figure 3 shows that three drugs from three different 
antihypertensive categories are perceived to display the best “medical support”, namely 
the calcium antagonist CA1, the diuretic D1, followed by the betablocker BB3. Turning 
to Figure 4, the lowest score of ACE2 on dimension F4 indicates that this is the 
antihypertensive with the highest perceived “adverse side effects”. 
 
The various classes of antihypertensive drugs, as doctors perceive them, are also plotted 
in Figures 2–4. These groups of drugs where identified using the following cluster 
analysis approach on the doctors’ derived perceptions (Lattin et al., 2003; Punj and 
Stewart, 1983). First, a hierarchical cluster analysis, using Ward’s method (Ward, 1963) 
with the squared Euclidean measure – which is the distance measure that should be used 
with this method (Everitt et al., 2001), was performed on the rotated factor scores for 
each drug. This solution was then confirmed with a non-hierarchical clustering 
procedure (K-means clustering) using the centroids from Ward’s method as seeds. For 
the analysis sample (66 % of doctors) four clusters gave the best statistical and 
interpretative solution (see the dendrogram in Figure 5). The K-means clustering 
solution produced the same results as for Ward’s method where four clusters were 
extracted. The same results were produced for the validation sample.  
  
[Insert Figure 2] 
 
[Insert Figure 3] 
 
[Insert Figure 4] 
 
[Insert Figure 5] 
 
Looking at Figure 5, from left to right, the first two categories to merge are the 
Alphablockers and Calcium Antagonists, resulting in the biggest of the four clusters; the 
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second cluster corresponds to the ACE class; the third cluster groups the two 
Betablockers BB3 and BB1; while the final cluster groups together the two diuretic 
drugs, D1 and D2. Only the betablocker BB2 was not correctly classified in its class, 
appearing with the Alphablockers and the Calcium Antagonists. The diuretic group of 
drugs is the last to merge, meaning that is perceived to be the antihypertensive 
therapeutic class that most differs from the other drugs classes in the analysis.  
 
Figure 2 reveals that the first perceptual dimension clearly separates the ACE group, 
which is viewed as offering the best “additional beneficial effects”, from the diuretic 
group, which is positioned at the other extreme of this dimension. Diuretics are also 
perceived to be the therapeutic group of ethical medicines with the worst “long term 
efficacy”. On the other hand, the fourth derived perceptual dimension reveals that the 
Diuretics group is perceived to produce the more desirable “adverse effects” of all 
antihypertensives (see Figure 4). Figure 4 also shows that Betablockers, which have the 
highest scores along the fifth dimension, are perceived to be the worst group in terms of 
“asthmatic and bronchitic suitability”; whereas Diuretics are the most appropriate drugs 
for hypertensive patients who suffer from these diseases. 
 
The Betablockers category, with variations on dimensions two, three, four and five, is 
the drug class with the biggest perceived differences. The Alphablockers category, each 
of which have similar, small differences along all dimensions, is perceived as the most 
homogeneous. The ACEs have the greatest variations along dimensions two and three, 
the Calcium Antagonists along dimensions three and four, and the Diuretics along the 
third dimension. This should be viewed in the context that the biggest variations in 
drugs within all drug classes always occur on a set of dimensions that include 
dimension 3. 
 
6. Determining the Relative Importance of the Main Evaluative Dimensions  
A form of multiple regression analysis called preference regression (Urban and Hauser 
(1993) was performed to determine the relative importance of the main evaluative 
dimensions.  The factor scores obtained for each doctor and drug were used as 
independent variables, with “reported prescribing frequency” (which can be regarded as 
a surrogate variable for drug market share) as the dependent variable. This analysis was 
first conducted on the analysis sample (66 % of doctors), before being run on the 
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validation sample. As suggested by Hair et al. (2006), model estimates from both 
samples were then compared for differences in the significant variables included, their 
sign, size, and relative importance. A table with all doctors and all drugs (vertical axis), 
and the five derived perceptual dimensions (horizontal axis) was built in each case.  
 
The multiple regression model assumes the existence of a linear relationship between 
the dependent and independent variables. To assess this assumption, the scatter-plots of 
the individual, dependent and independent variables were visually inspected. This 
observation did not indicate any non-linear relationships between the dependent and 
independent variables. The stepwise procedure was then used to estimate the regression 
model. As Table 5 shows, the adjusted coefficient of determination (adjusted R
2
) 
increases from 42.8 % to 43.0 % when Factor 5 is added to the model and from 43.0 % 
to 43.1 % when Factor 4 is added. Consequently, only the first three factors are used in 
the final derived model. This is a more parsimonious model and is therefore considered 
the best model using factors as independent regression variables. 
 
[Insert Table 5] 
 
Results of the multiple regression model derived with the first three factors are shown in 
Table 6. Multicollinearity is not a problem in this regression model since the 
independent variables, the varimax rotated factors, are by definition uncorrelated. 
Consequently, the tolerance and VIF values in Table 6 are 1.0, as expected.  This 
regression model was estimated after nine outliers (observations showing standardised 
residuals with absolute value greater than 3.0) had been excluded, which slightly 
improved the regression results – e.g., the adjusted R
2
 for the model with three factors in 
Table 5 rose from 0.428 to 0.452, in Table 6. 
 
Equation (1) shows the derived linear regression model with the three most important 
factors explaining 45 % of the variation in “reported prescribing frequency”.  
 
(1) RPRESC = 4.70 + 0.54 F1 + 0.49 F2 + 1.05 F3;  R
2
 Adj. = 0.45 
      (152.75) (17.68)    (16.08)     (34.22)        
 
As expected, “reported prescribing frequency” increases as the first dimension 
“additional beneficial effects” increases, with the increase of the second dimension 
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“long term efficacy”, and with the increase of the third dimension perceived “medical 
support”. Looking at the Beta values shown in Table 6, the most important variable in 
this regression model is Factor 3, with a figure of 0.55, approximately double the weight 
of Factor 1 and Factor 2. 
 
[Insert Table 6] 
 
To verify whether assumptions on which the regression analysis model rests are met, 
the linearity, homocedasticity, independence of residuals and normality assumptions 
were examined. Linearity of the overall equation can be judged by observing the plot of 
standardised residuals against the predicted values of the independent variable “reported 
prescribing frequency” (Hair et al., 2006). This plot revealed no non-linear patterns 
within the data, suggesting that the application of the linear model is adequate. 
Moreover, the standardised partial regression plots for each independent variable 
showed no non-linear patterns. The plots also reveal that the relationship of Factor 3 is 
the most well linearly defined. The violation of equality of variance assumption can be 
checked by plotting the standardised residuals against the independent and dependent 
variables, then observing increases or decreases in the spread of residuals as the values 
of these variables change. As the standardised residuals plots for each independent 
variable revealed no increasing or decreasing pattern of residuals, this assumption is 
validated. To check the independence of residuals, the residuals were plotted against all 
independent variables and the case number variable. No pattern was found, suggesting 
that residuals are independent from one observation to another. A visual inspection of 
the normal probability plot of the standardised residuals revealed expected versus 
observed values close to the diagonal, suggesting it is reasonable to assume approximate 
normality of regression residuals – see Figure 6. 
 
[Insert Figure 6] 
 
Validation of the regression model was achieved by comparing the stepwise results 
from equations (1) and (1a), which are from different samples, to ensure robustness: 
 
(1a) RPRESC = 4.78 + 0.55 F1 + 0.40 F2 + 1.20 F3; R
2
 Adj. = 0.49. 
       (114.03) (13.17)    (9.21)      (28.97)     
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7. Using Doctors’ Perceptions to Support Strategic Marketing Decisions 
Concerning Ethical Drugs 
The perceptual analysis enables the effects of positioning strategies to be monitored and 
better competitive positions for ethical antihypertensive drugs to be identified.  Using 
ACE2 and ACE3 as an example, the perceptual maps show that ACE2 is beaten by 
ACE3 on the second dimension, “long term efficacy”. This is because ACE3 is 
perceived to have a simpler dosage regime than ACE2. In fact, both drugs have similar 
scores on all except one of the attributes that load high on the second perceptual 
dimension. The exception is the variable “a very simple dosage regime”, with ACE3 
and ACE2 showing average scores of 2.5 and 3.7, respectively. These perceptions 
reflect reality, since ACE3 was designed to have a simpler dosage regime than ACE2.  
 
The situation relating to ACE1 and ACE4, which both contain exactly the same 
chemical entity, should also be considered.  As Company A already had the leading 
ACE3 in its portfolio when ACE1 was invented, it decided to position ACE1 as 
particularly suitable for elderly patients. Meanwhile Company B, which licensed the 
same chemical entity from Company A, marketed ACE4 as a general ACE. As Figures 
2–4 reveal, doctors perceive the two brands differently, even though they contain the 
same active ingredient. 
 
The derived perceptual maps also reveal that there is a strategic gap for a new 
antihypertensive that excels in both dimensions F1 and F3 (see Figure 3). Alternatively, 
this gap could de fulfilled, for example, if it would be possible to improve considerably 
the score of CA1 on the dimension F1, since this drug already displays the best 
“medical support”, or by improving considerably the score of ACE2 on dimension F3, 
since ACE2 already offers the best “additional beneficial effects” of all 
antihypertensives in sample. 
 
Perceptual maps are helpful to identify those ethical drugs which are not differentiated 
in the minds of prescribers – those which are those located close to the origin. One such 
example is CA2 which is always very close to the origin in Figures 2–4. 
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Pharmaceutical marketing managers can use the linear model derived from the analysis 
to guide the search for better competitive positions for antihypertensive drugs.   The 
relationships captured in equation (1) can be used to explore alternative ways to 
increase the “reported prescribing frequency” and market share of brands. Taking ACE4 
as an example, its “reported prescribing frequency” can be improved more effectively if 
it is possible to enhance the drug’s scores along the dimensions F3 - “medical support”, 
F1 - “additional beneficial effects” and F2 - “long term efficacy”, by this sequence (see 
Beta values in Table 6). 
 
Where marketing managers are primarily concerned with competition within the ACE 
group, attention should be focused on the third and first dimensions, since ACE4 is 
already perceived as the best option on dimension two (see Figures 2 and 3). Looking at 
the first dimension, ACE4 has to improve its score along one or more of the original 
variables which load highly on this dimension. However, analysis of these original 
variables revealed that ACE4 already has similar scores to its competitors. This implies 
that unless new information about the drug is provided, it may be difficult to improve 
the scores for these variables. To improve its score along the third dimension, the 
analysis of the original variables that load high on dimension three revealed that the 
variable where ACE4 is at a greater competitive disadvantage in the ACE group is the 
variable WRB. Therefore efforts are needed to improve the degree to which ACE4 is 
perceived to be “widely recommended by local consultants”. 
 
8. Conclusions, Limitations and Suggestions for Further Work 
This study has been the first to apply factor analysis to develop perceptual maps 
revealing the key choice dimensions and perceived competitive positions of ethical  
pharmaceutical brands. In addition, this is the first time that multivariate perceptual 
mapping methods have been used to investigate the antihypertensives market. 
Moreover, this research has analysed a large set of fourteen ethical drugs, contrasting to 
previous studies which have produced perceptual maps for a maximum of seven 
competing ethical drugs. As has been argued, such simultaneous analysis of a large set 
of prescription drugs might benefit pharmaceutical managers who are operating in the 
most competitive ethical markets. The methodology used in this research aims to 
improve the knowledge of how doctors choose the drugs they prescribe and to support 
strategic marketing decisions in the ethical pharmaceutical industry.  
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Factor analysis has revealed that UK family doctors use five dimensions to evaluate 
competitive antihypertensive drugs. According to Urban and Hauser (1993) “there is 
evidence that customers tend to simplify judgments by reducing dimensionality to 
prevent cognitive strain and information overload”. The fact that doctors in this research 
use a small number of dimensions to perceive prescription drugs suggests that doctors 
share this behaviour with customers in general. 
 
These dimensions are the “additional beneficial effects” of the drug, the “long term 
efficacy” of the drug, the perceived “medical support” the drug receives from 
professionals, the “adverse side effects” of the drug, and finally, the “asthmatic and 
bronchitic suitability” of the drug.  These results
4
, in particular the dimensions “long 
term efficacy” and “adverse side effects”, corroborate the findings obtained by Neidell 
(1969), who also found two similar perceptual dimensions, one related to 
potency/effectiveness and the other to undesired side effects of the ethical brand. In the 
study by Hurrell et al. (1997), one of the perceptual map’s dimensions was related to the 
“strength” of the prescription drug.  This might indicate that doctors use the dimensions 
related to efficacy and side effects (undesired) to perceive and evaluate prescription 
drugs across various ethical markets.  
 
Perceptual maps were then built showing the perceived competitive positions of the 
sampled ethical brands, using average factor scores on each of the derived perceptual 
dimensions. Cluster analysis revealed that doctors perceive there to be four distinctive 
categories of antihypertensives. One cluster groups together Alphablockers and Calcium 
Antagonists; a second cluster corresponds to the ACE group; a third cluster groups the 
two Diuretics; and a fourth cluster groups two of the Betablockers. Only one 
betablocker medicine was not correctly classified in its class. 
 
                                                 
4
 Results of the present research are not comparable to those obtained by DeSarbo et al. (2002) who 
derived a two dimensional map built on preference data alone. Consequently, their map is noticeable 
different from the maps derived in the present research. DeSarbo et al. (2002) make the following 
observations about their dimensions, commenting that “the horizontal dimension reflects brand 
ingredients” and the “vertical dimension correlates highly with market share”. 
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Multiple regression analysis using the scores of the derived perceptual dimensions as 
independent variables, and “reported prescribing frequency” as the dependent variable, 
was carried out to determine the relative importance of the main evaluative dimensions. 
The findings show that UK family doctors prefer antihypertensive drugs with higher 
perceived “additional beneficial effects”, with higher perceived “long term efficacy”
5
, 
and with higher perceived “medical support”. Moreover, it was found that the most 
single important dimension in determining “reported prescribing frequency” is the 
perceived “medical support”. Results have shown that the regression model with the 
first three main perceptual dimensions explains 45 % of the total variance of the 
dependent “reported prescribing frequency” variable. The methodology used in this 
research provides pharmaceutical marketing managers with the means to identify more 
appropriate competitive positions for ethical antihypertensives. 
 
This research contributes to the strategic marketing and operational research knowledge 
fields by showing that multivariate approaches which have been successfully used in 
other industries can be applied to the ethical pharmaceutical market. More specifically 
the work demonstrates that these quantitative approaches can be used to refine the 
targeting and positioning of drugs to the doctors who prescribe them.  This is possible 
because the analysis improves existing knowledge about how doctors choose the drugs 
they prescribe.  
 
This research has practical implications for the ethical pharmaceutical industry, 
demonstrating a multivariate methodology which is new to the industry. The application 
provides pharmaceutical managers with a tool for improving strategic marketing 
decisions concerning ethical drugs. Finally, this work is relevant to governments and 
healthcare bodies involved in shaping policy on prescribing. The decisions these policy 
makers take may force doctors to alter their prescribing habits.  In such circumstances it 
is important to understand how the perceptions and preferences of doctors for the 
medicines they prescribe will change. This methodology can be used to monitor the 
                                                 
5
 This finding is not in line with research results reported by Neidell (1969) suggesting that the average 
doctor prefers ataractic drugs with intermediate rather than higher potency/effectiveness. On the other 
hand, he also reported that doctors prefer anorectic drugs with higher potency. 
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effects of health care policies on ethical drugs on the perceptions, preferences and actual 
prescribing habits of doctors.  
 
There are a number of opportunities for further research which builds upon the findings 
presented here. Given that this research has used self-reported rather than actual 
prescribing frequency, it would be appropriate to consider how well self-reported 
measures adhere to actual prescribing behaviour. The research also suffers from general 
criticisms about compositional studies, since doctors have been asked direct questions 
about attribute variables. This raises the question of whether doctors actually use the 
attributes included in the questionnaire when making prescribing decisions, or whether 
some would not have been considered had they not been included in the questions. 
Future research using decompositional approaches would be welcomed to clarify this 
issue and to verify whether compositional and decompositional approaches lead to the 
same results, where prescription drugs are analysed. It would also be interesting to 
compare the results from the vector model approach with those resulting from an ideal 
model approach. This would help examine whether doctors use perceptual dimensions 
where “more (or less) is better” fits the prescriber population as a whole. Research 
examining the effect of variables which intervene between intention and behaviour and 
change prescribing intention is also warranted. 
 
The methodology adopted in this paper could be applied across a range of situations, 
including to different segments of doctors, to those working in other countries or in 
different types of healthcare organizations. This would enable doctors subjected to 
different prescribing policies to be studied. A longitudinal research design would enable 
changing perceptions over time to be examined. Other ethical drugs and different 
perceptual variables could also be examined. Finally, other methodologies should be 
tried; in particular structural equation modelling could be used to test whether the factor 
and regression results empirically obtained in this research hold in other prescribing 
situations. 
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Code Variable name 
  
OLT Offers long term control of hypertension 
ACP A cardio protective drug 
HRI Has relatively infrequent side effects 
EFS Effective for severe cases of hypertension 
ARE A relatively expensive drug 
VSA Very suitable for asthmatic and bronchitic patients 
AVS A very simple dosage regime 
TTC Tends to cause postural hypotension 
VSE Very suitable for elderly patients 
WRB Widely recommended by local consultant 
IQL Improves patient’s quality of life 
UFM A useful drug for use in mild cases of  hypertension 
WSB Well supported by clinical trials 
VSY Very suitable for younger hypertensives 
OWP Occasionally will produce severe side effects 
FLT First line treatment in hypertension 
UDC Useful for difficult hypertensive cases 
ELS Effectively lowers systolic blood pressure 
BSL Has a beneficial effect on serum lipid profile 
RLV Regresses left ventricular hypertrophy 
BWC Benefits the whole cardiovascular system 
 
Table 1 - Variables used to evaluate ethical drugs  
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Factor Eigenvalue % of variance Cumulative 
% of  variance 
    
1 6.4 30.6 30.6 
2 2.5 12.1 42.6 
3 1.4 6.7 49.4 
4 1.2 5.9 55.3 
5 1.0 4.8 60.1 
6 0.8 4.0 64.1 
7 0.7 3.5 67.6 
8 0.7 3.2 70.8 
9 0.7 3.2 74.0 
10 0.6 3.1 77.1 
11 0.6 3.0 80.0 
 
Table 3 - First Eleven Factors Extracted using Principal Components Method 
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Var. 
Code 
Variable 
 
F1 F2 F3 F4 F5 Co
mm
unal
ity 
        
BWC Benefits the whole cardiovascular 
system 
0.73     0.62 
RLV Regresses left ventricular hypertrophy 0.69     0.53 
BSL Has a beneficial effect on serum lipid 
profile 
0.65     0.53 
UDC Useful for difficult hypertensive cases 0.63 0.43    0.64 
ACP A cardio protective drug 0.62    -0.44 0.66 
IQL Improves patient’s quality of life 0.58     0.57 
VSY Very suitable for younger hypertensives 0.57     0.63 
ARE A relatively expensive drug 0.41     0.55 
OLT Offers long term control of 
hypertension 
 0.73    0.65 
AVS A very simple dosage regime  0.63    0.58 
ELS Effectively lowers systolic blood  
pressure 
 0.60    0.52 
EFS Effective for severe cases of  
hypertension 
0.50 0.60    0.65 
WSB Well supported by clinical trials  0.56    0.49 
FLT First line treatment in hypertension   0.80   0.73 
UFM A useful drug for use in mild cases of 
hypertension 
  0.76   0.68 
WRB Widely recommended by local 
consultant 
  0.57   0.52 
VSE Very suitable for elderly patients   0.46  0.46 0.62 
TTC Tends to cause postural hypotension    0.73  0.60 
OWP Occasionally will produce severe side 
effects 
   0.72  0.60 
HRI Has relatively infrequent side effects    -0.49  0.55 
VSA Very suitable for asthmatic and 
bronchitic patients 
    0.81 0.72 
        
 Percentage of total variance 
explained (%)  
19 13 12 9 8  
 
Table 4 - Five Factor Solution obtained with Principal Components Method and 
Varimax Rotation  
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Change Statistics Model R R 
Square 
Adjusted 
R 
Square 
Std. 
Error of 
the 
Estimate 
R 
Square 
Change 
F 
Change 
df1 df2 Sig. F 
Change 
          
1 .535 (a) .287 .286 1.6096 .287 845.349 1 2105 .000 
2 .604 (b) .365 .364 1.5189 .078 259.904 1 2104 .000 
3 .655 (c) .429 .428 1.4410 .064 234.623 1 2103 .000 
4 .656 (d) .431 .430 1.4388 .002 7.489 1 2102 .006 
5 .657 (e) .432 .431 1.4375 .001 4.857 1 2101 .028 
 
a. Predictors: (Constant), F3 
b. Predictors: (Constant), F3, F1 
c. Predictors: (Constant), F3, F1, F2 
d. Predictors: (Constant), F3, F1, F2, F5 
e. Predictors: (Constant), F3, F1, F2, F5, F4 
f. Dependent Variable: RPRESC 
 
Table 5 - Stepwise Multiple Regression Model Summary, with Five Factors as 
Independent Variables  
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Dependent Variable: RPRESC       
Variable(s) Entered:  F1, F2, F3       
         
Multiple R 0.673        
R Square 0.453        
Adjusted R 
Square 
0.452        
Standard 
Error 
1.408        
         
ANOVA        
 df Sum of 
Squares 
Mean 
Square 
F Sig.    
Regression 3 3440.174 1146.725 578.364 0.000    
Residual 2094 4151.784 1.983      
         
Variable Variable 
Name 
B Std. 
Error 
Beta Tolerance VIF t Sig. 
F1 Additional 
beneficial 
effects 
0.542 0.031 0.286 1.000 1.000 17.678 0.000 
F2 Long term 
efficacy 
0.493 0.031 0.260 1.000 1.000 16.076 0.000 
F3 Medical 
support 
1.054 0.031 0.553 1.000 1.000 34.218 0.000 
(Constant) 4.696 0.031    152.750 0.000 
 
Table 6 - Regression Estimates of “Reported Prescribing Frequency”, with Three 
Factors as Independent Variables (with the outliers removed) 
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Figure 1 - Scree Plot 
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Figure 2 - Perceptual map “Additional beneficial effects” vs “Long term efficacy” 
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Figure 3 - Perceptual map “Additional beneficial effects” vs “Medical support” 
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Figure 4 - Perceptual map “Asthmatic and bronchitic suitability” vs “Adverse side 
effects” 
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Figure 5 - Dendrogram from the Ward’s Method 
                           Rescaled Distance Cluster Combine
     C A S E       0         5        10        15        20        25
  Label       Num  +---------+---------+---------+---------+---------+
  Cardura       8   
  Hytrin        9    
  Istin         2    
  Tildiem       3          
  AdalatR20     1           
  Monocor      13          
  Innovace      6                       
  Zestril       7                       
  Carace        4                                       
  Capoten       5                                                 
  Inderal      12                            
  Tenormin     14                                              
  Moduretic    10   
  Navispare    11   
+---------+ 
  AB1   8   
  AB2   9   
  CA2   2   
  CA3   3  
  CA1     1   
  BB2   13  
  ACE3   6
  ACE4     7
  ACE1     4   
  ACE2     5 
  BB1   12   
  BB3    14   
  D1       10   
  D2       11   
          
          
  
  
   
 
        
       
       
      
       
        
     
       
      
    
    
ACCEPTED MANUSCRIPT 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 42 
 
 
Figure 6 – Normal Probability Plot of Regression Standardised Residuals  
